Antisoma reports outcome of AS1413 phase III trial
by on Monday, January 31st, 2011 | No Comments
… announces that the ACCEDE phase III trial of AS1413 (amonafide) in secondary acute myeloid leukaemia (secondary AML) did not meet its primary endpoint. Development of AS1413 will be discontinued. …
See the rest here: Antisoma reports outcome of AS1413 phase III trial